CS-101 is Shanghai-based CorrectSequence's lead candidate, which it is developing for treating sickle-cell disease and ...

Scientists and physicians can better assess precision genome editing technology using a new method made public today by St.

CHANGE-seq-BE was developed to enable scientists to better understand base editors, an important class of CRISPR precise genome editors.

Gene therapy has long promised to provide a solution for genetic blood disorders, but delivering on that promise has proven complex due to challenges including difficulties delivering the editing ...

Find how Circularization for High-throughput Analysis of Nuclease Genome-wide Effects by Sequencing Base Editors ...

I was looking forward to seeing how Beam Therapeutics would do in their clinical trials of single-base DNA editing therapies, and this morning we have a readout. It was a very small trial: three ...

In a landscape where precision is paramount, the base editing market is emerging as a cornerstone of modern biotechnology, ...

CS-101 is Shanghai-based CorrectSequence's lead candidate, which it is developing for treating sickle-cell disease and ...